bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary figure S1 from Antagonizing the Hedgehog Pathway with Vismodegib Impairs Malignant Pleural Mesothelioma Growth In Vivo by Affecting Stroma
Authors: Meerang Mayura , Bérard Karima , Felley-Bosco Emanuela , Lauk Olivia , Vrugt Bart , Boss Andreas , Kenkel David , Broggini-Tenzer Angela , Stahel Rolf A. , Arni Stephan , Weder Walter , Opitz Isabelle
Published: April 2023

No correlation between Dhh and Gli1 expression levels in rat MPM cells
Supplementary Table 11 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

Results from the dasatinib target siRNA screen, see also Figure S6
Supplementary Table 10 from Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Authors: Miller Rowan E. , Brough Rachel , Bajrami Ilirjana , Williamson Chris T. , McDade Simon , Campbell James , Kigozi Asha , Rafiq Rumana , Pemberton Helen , Natrajan Rachel , Joel Josephine , Astley Holly , Mahoney Claire , Moore Jonathan D. , Torrance Chris , Gordan John D. , Webber James T. , Levin Rebecca S. , Shokat Kevan M. , Bandyopadhyay Sourav , Lord Christopher J. , Ashworth Alan
Published: April 2023

MS Stats output from dasatinib bead proteomics, see also Figure 3
Supplementary Table S6 from Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
Authors: Azuara Daniel , Santos Cristina , Lopez-Doriga Adriana , Grasselli Julieta , Nadal Marga , Sanjuan Xavier , Marin Fátima , Vidal Joana , Montal Robert , Moreno Victor , Bellosillo Beatriz , Argiles Guillem , Elez Elena , Dienstmann Rodrigo , Montagut Clara , Tabernero Josep , Capellá Gabriel , Salazar Ramon
Published: April 2023

Progression-Free Survival (PFS) and Overall Survival (OS) after anti-EGFR treatment (adding cut-off 2%)
Supplementary Table S4 from Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
Authors: Azuara Daniel , Santos Cristina , Lopez-Doriga Adriana , Grasselli Julieta , Nadal Marga , Sanjuan Xavier , Marin Fátima , Vidal Joana , Montal Robert , Moreno Victor , Bellosillo Beatriz , Argiles Guillem , Elez Elena , Dienstmann Rodrigo , Montagut Clara , Tabernero Josep , Capellá Gabriel , Salazar Ramon
Published: April 2023

Comparison between sensitive vs chemorefractory population
Supplementary Table S3 from Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
Authors: Azuara Daniel , Santos Cristina , Lopez-Doriga Adriana , Grasselli Julieta , Nadal Marga , Sanjuan Xavier , Marin Fátima , Vidal Joana , Montal Robert , Moreno Victor , Bellosillo Beatriz , Argiles Guillem , Elez Elena , Dienstmann Rodrigo , Montagut Clara , Tabernero Josep , Capellá Gabriel , Salazar Ramon
Published: April 2023

Mutations detected by conventional qPCR and by highly-sensitive dPCR
Supplemental Figure Legends from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
Authors: Li Long-Shan , Reddy Srilakshmi , Lin Zhen-Hua , Liu Shuangping , Park Hyunsil , Chun Stephen G. , Bornmann William G. , Thibodeaux Joel , Yan Jingsheng , Chakrabarti Gaurab , Xie Xian-Jin , Sumer Baran D. , Boothman David A. , Yordy John S.
Published: April 2023

Supplemental Figure Legends; Supplemental Table Legends
Supplemental Tables 1-3 and Supplemental Figure Legends from Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase Signalosome
Authors: Liu Miao , Feng Li-Xing , Sun Peng , Liu Wang , Mi Tian , Lei Min , Wu Wanying , Jiang Baohong , Yang Min , Hu Lihong , Guo De-An , Liu Xuan
Published: April 2023

Supplemental Table S1. Primer sequences of primers used in PCR analysis; Supplemental Table S2. Antibodies used in laser scanning confocal microscopy and Western blotting assay; Supplemental Table S3. RNA-seq results of 36 differentially expressed genes (p<0.01) between Hep3B and SK-HEP-1cells; Supplemental Figure Legends
Supplemental Figure S3 from Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase Signalosome
Authors: Liu Miao , Feng Li-Xing , Sun Peng , Liu Wang , Mi Tian , Lei Min , Wu Wanying , Jiang Baohong , Yang Min , Hu Lihong , Guo De-An , Liu Xuan
Published: April 2023

STRING analysis results of protein-protein interactions among the 36 differentially expressed proteins.
Supplemental Figure S2 from Knockdown of Apolipoprotein E Enhanced Sensitivity of Hep3B Cells to Cardiac Steroids via Regulating Na+/K+-ATPase Signalosome
Authors: Liu Miao , Feng Li-Xing , Sun Peng , Liu Wang , Mi Tian , Lei Min , Wu Wanying , Jiang Baohong , Yang Min , Hu Lihong , Guo De-An , Liu Xuan
Published: April 2023

A, Cell viability (MTT assay) of four kinds of hepatoma cells and one kind of human hepatic cells treated with various concentrations of OUA for 72 h. B, Cell viability of cells treated with various concentrations of DIG for 72 h. C, Cell viability (MTT assay) of Hep3B cells and SK-HEP-1 cells treated with various concentrations of cisplatin for 72 h. Data presented was mean {plus minus} SEM of three independent experiments. Significantly different vs control groups (* p < 0.05, **p<0.01).
Supplemental Figure Legends from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
Authors: Giulino-Roth Lisa , van Besien Herman J. , Dalton Tanner , Totonchy Jennifer E. , Rodina Anna , Taldone Tony , Bolaender Alexander , Erdjument-Bromage Hediye , Sadek Jouliana , Chadburn Amy , Barth Matthew J. , Dela Cruz Filemon S. , Rainey Allison , Kung Andrew L. , Chiosis Gabriela , Cesarman Ethel
Published: April 2023

Supplemental Figure Legends
Supplementary Figures 1-4 and Supplementary Methods from Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment
Authors: Rucki Agnieszka A. , Xiao Qian , Muth Stephen , Chen Jianlin , Che Xu , Kleponis Jennifer , Sharma Rajni , Anders Robert A. , Jaffee Elizabeth M. , Zheng Lei
Published: April 2023

Supplementary Figure 1. The rate of proliferation is the same in the orthotopic and transgenic KPC mouse models Supplementary Figure 2. Single c-Met or Hh inhibitor treatment leads to the enhanced expression of the other target and the combination of both c-Met and Hh inhibitors suppresses the expression of both targets more effectively Supplementary Figure 3. Prolonged treatment of single HGF/c-Met or Hh inhibitor leads to resistance to single targeted agents, which can be overcome by the combination of both c-Met and Hh inhibitors. Supplementary Figure 4. Lentiviral knockdown of c-Met in KPC tumor cells results in decrease of Shh expression. Supplementary Materials and Methods
Supplemental Figure 5 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
Authors: Giulino-Roth Lisa , van Besien Herman J. , Dalton Tanner , Totonchy Jennifer E. , Rodina Anna , Taldone Tony , Bolaender Alexander , Erdjument-Bromage Hediye , Sadek Jouliana , Chadburn Amy , Barth Matthew J. , Dela Cruz Filemon S. , Rainey Allison , Kung Andrew L. , Chiosis Gabriela , Cesarman Ethel
Published: April 2023

BL PDX tumors retain characteristics of primary BL.
Supplemental Figure 2 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma
Authors: Giulino-Roth Lisa , van Besien Herman J. , Dalton Tanner , Totonchy Jennifer E. , Rodina Anna , Taldone Tony , Bolaender Alexander , Erdjument-Bromage Hediye , Sadek Jouliana , Chadburn Amy , Barth Matthew J. , Dela Cruz Filemon S. , Rainey Allison , Kung Andrew L. , Chiosis Gabriela , Cesarman Ethel
Published: April 2023

BL tumors overexpress Hsp90
Supplementary Figure S4 from AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Authors: Min Ahrum , Im Seock-Ah , Jang Hyemin , Kim Seongyeong , Lee Miso , Kim Debora Keunyoung , Yang Yaewon , Kim Hee-Jun , Lee Kyung-Hun , Kim Jin Won , Kim Tae-Yong , Oh Do-Youn , Brown Jeff , Lau Alan , O'Connor Mark J. , Bang Yung-Jue
Published: April 2023

The level of ATM activity is different depending on AZD6738 sensitivity
Supplementary Figure S3 from AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Authors: Min Ahrum , Im Seock-Ah , Jang Hyemin , Kim Seongyeong , Lee Miso , Kim Debora Keunyoung , Yang Yaewon , Kim Hee-Jun , Lee Kyung-Hun , Kim Jin Won , Kim Tae-Yong , Oh Do-Youn , Brown Jeff , Lau Alan , O'Connor Mark J. , Bang Yung-Jue
Published: April 2023

ATM activation is associated with resistance to AZD6738
Table S4 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Authors: Santos Cristina , Azuara Daniel , Garcia-Carbonero Rocio , Alfonso Pilar Garcia , Carrato Alfredo , Elez Mª Elena , Gomez Auxiliadora , Losa Ferran , Montagut Clara , Massuti Bartomeu , Navarro Valenti , Varela Mar , Lopez-Doriga Adriana , Moreno Victor , Valladares Manuel , Manzano Jose Luis , Vieitez Jose Maria , Aranda Enrique , Sanjuan Xavier , Tabernero Josep , Capella Gabriel , Salazar Ramon
Published: April 2023

Likelihood ratio of positive test analysis (anti-EGFR cohort). Higher probability coefficient values indicate better capacity to predict response.
Supplementary Figure S1 from AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Authors: Min Ahrum , Im Seock-Ah , Jang Hyemin , Kim Seongyeong , Lee Miso , Kim Debora Keunyoung , Yang Yaewon , Kim Hee-Jun , Lee Kyung-Hun , Kim Jin Won , Kim Tae-Yong , Oh Do-Youn , Brown Jeff , Lau Alan , O'Connor Mark J. , Bang Yung-Jue
Published: April 2023

Gastric cancer cell lines show heterogeneous responses to AZD6738
Table S3 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Authors: Santos Cristina , Azuara Daniel , Garcia-Carbonero Rocio , Alfonso Pilar Garcia , Carrato Alfredo , Elez Mª Elena , Gomez Auxiliadora , Losa Ferran , Montagut Clara , Massuti Bartomeu , Navarro Valenti , Varela Mar , Lopez-Doriga Adriana , Moreno Victor , Valladares Manuel , Manzano Jose Luis , Vieitez Jose Maria , Aranda Enrique , Sanjuan Xavier , Tabernero Josep , Capella Gabriel , Salazar Ramon
Published: April 2023

Frequencies and distribution of mutations in the study population (N = 583)
Supplementary Figure Legends from AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Authors: Min Ahrum , Im Seock-Ah , Jang Hyemin , Kim Seongyeong , Lee Miso , Kim Debora Keunyoung , Yang Yaewon , Kim Hee-Jun , Lee Kyung-Hun , Kim Jin Won , Kim Tae-Yong , Oh Do-Youn , Brown Jeff , Lau Alan , O'Connor Mark J. , Bang Yung-Jue
Published: April 2023

Supplementary Figure Legends
Conflict of Interest Form from AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Authors: Min Ahrum , Im Seock-Ah , Jang Hyemin , Kim Seongyeong , Lee Miso , Kim Debora Keunyoung , Yang Yaewon , Kim Hee-Jun , Lee Kyung-Hun , Kim Jin Won , Kim Tae-Yong , Oh Do-Youn , Brown Jeff , Lau Alan , O'Connor Mark J. , Bang Yung-Jue
Published: April 2023

Conflict of Interest Form
Table S1 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
Authors: Santos Cristina , Azuara Daniel , Garcia-Carbonero Rocio , Alfonso Pilar Garcia , Carrato Alfredo , Elez Mª Elena , Gomez Auxiliadora , Losa Ferran , Montagut Clara , Massuti Bartomeu , Navarro Valenti , Varela Mar , Lopez-Doriga Adriana , Moreno Victor , Valladares Manuel , Manzano Jose Luis , Vieitez Jose Maria , Aranda Enrique , Sanjuan Xavier , Tabernero Josep , Capella Gabriel , Salazar Ramon
Published: April 2023

Primers and conditions of PCR amplicons. Panel of mutations, primers and probe sequences
Figure S1 from Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
Authors: Tabernero Josep , Ohtsu Atsushi , Muro Kei , Van Cutsem Eric , Oh Sang Cheul , Bodoky György , Shimada Yasuhiro , Hironaka Shuichi , Ajani Jaffer A. , Tomasek Jiri , Safran Howard , Chandrawansa Kumari , Hsu Yanzhi , Heathman Michael , Khan Azhar , Ni Lan , Melemed Allen S. , Gao Ling , Ferry David , Fuchs Charles S.
Published: April 2023

Figure S1 shows the predicted ramucirumab concentration (μg/mL) over an 8-mg/kg dosing regimen to predicted steady-state.
Supplementary Figure 2 from Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53
Authors: Karan Goutam , Wang Huaiyu , Chakrabarti Amit , Karan Sukanya , Liu Zhigang , Xia Zhiqiang , Gundluru Mahesh , Moreton Stephen , Saunthararajah Yogen , Jackson Mark W. , Agarwal Mukesh K. , Wald David N.
Published: April 2023

HdmX overexpression does not impair CTX1-mediated killing in leukemia cells.
Supplementary Figures S1-S13 from Reactivation of the p90RSK–CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2–M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC
Authors: Chatterjee Suman , Huang Eric H.-B. , Christie Ian , Burns Timothy F.
Published: April 2023

Supplementary Figure S1: Acquired resistance to ganetespib in KRAS mutant NSCLC cell line, H460, leads to loss of ganetespib induced G2/M arrest; Supplementary Figure S2: p90RSK overexpression leads to bypass of ganetespib induced G2/M arrest in an isoform specific manner; Supplementary Figure S3: Pharmacological inhibition of p90RSK leads to dose dependent G2/M arrest; Supplementary Figure S4: Acquired resistance to ganetespib in KRAS mutant NSCLC cell lines leads to upregulation of several critical G2/M checkpoint regulators; Supplementary Figure S5: CDC25C overexpression in KRAS mutant NSCLC cell lines; Supplementary Figure S6: Genetic silencing of CDC25C in parental as well as GR KRAS mutant NSCLC cells; Supplementary Figure S7: Overexpression of CDC25C sensitizes KRAS mutant NSCLC cells to CDC25C inhibitors; Supplementary Figure S8: Additive combinatorial activity of ganetespib and NSC-663284 observed in A549 cells; Supplementary Figure S9: Ganetespib resistance induced by CDC25C overexpression leads to ERK/p90RSK dependence; Supplementary Figure S10: Additive combinatorial activity of ganetespib and Bi-D1870 observed in KRAS mutant NSCLC cell - H460; Supplementary Figure S11: Additive combinatorial activity of ganetespib and Bi-D1870 observed in KRAS mutant NSCLC cell - A549; Supplementary Figure S12: Combinatorial activities of p90RSK inhibitor (BI-D1870), ERK1/2 inhibitor (SCH7729), and CDC25C inhibitor (NSC-663284) in H460-GR10 cells; Supplementary Figure S13: Combinatorial activities of p90RSK inhibitor (BI-D1870), ERK1/2 inhibitor (SCH7729), and CDC25C inhibitor (NSC-663284) in A549-GR100 cells.
Supplementary Figure Legends and Supplementary Tables S1-S3 from Reactivation of the p90RSK–CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2–M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC
Authors: Chatterjee Suman , Huang Eric H.-B. , Christie Ian , Burns Timothy F.
Published: April 2023

Supplementary Table S1: Primary and secondary antibodies used in the study; Supplementary Table S2: Sequences for CDC25C shRNA (5' - 3'); Supplementary Table S3: IC50 values for in vitro cytotoxicity after 72 hours of treatment with different drugs in KRAS mutant NSCLC cell lines examined.
Supplementary Figure 1 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Authors: Punnoose Elizabeth A. , Leverson Joel D. , Peale Franklin , Boghaert Erwin R. , Belmont Lisa D. , Tan Nguyen , Young Amy , Mitten Michael , Ingalla Ellen , Darbonne Walter C. , Oleksijew Anatol , Tapang Paul , Yue Peng , Oeh Jason , Lee Leslie , Maiga Sophie , Fairbrother Wayne J. , Amiot Martine , Souers Andrew J. , Sampath Deepak
Published: April 2023

Disruption of BCL-2-BIM complexes in venetoclax-sensitive HMCLs
Legends for Tables S1 to S3 and Figures S1 to S5 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Authors: Punnoose Elizabeth A. , Leverson Joel D. , Peale Franklin , Boghaert Erwin R. , Belmont Lisa D. , Tan Nguyen , Young Amy , Mitten Michael , Ingalla Ellen , Darbonne Walter C. , Oleksijew Anatol , Tapang Paul , Yue Peng , Oeh Jason , Lee Leslie , Maiga Sophie , Fairbrother Wayne J. , Amiot Martine , Souers Andrew J. , Sampath Deepak
Published: April 2023

Legends for Tables S1 to S3 and Figures S1 to S5
Supplementary Table S1 and Figures S1-6 from Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
Authors: Dai Xiaoyun , Ahn Kwang Seok , Wang Ling Zhi , Kim Chulwon , Deivasigamni Amudha , Arfuso Frank , Um Jae-Young , Kumar Alan Prem , Chang Young-Chae , Kumar Dhiraj , Kundu Gopal C. , Magae Junji , Goh Boon Cher , Hui Kam Man , Sethi Gautam
Published: April 2023

Table S1. The primer sequences of different genes; Figure S1: The chemical structure of ASC; Figure S2: ASC selectively enhanced DOX cytotoxicity in HCC cells; Figure S3: Immunofluorescence analysis of Vimentin protein; Figure S4: ASC co-treatment decreased DOX-induced migration in HCC cells; Figure S5: The combinatorial effect of ASC and DOX could be reversed by treatment with proteasome inhibitor; Figure S6: The combination treatment inhibits the expression of STAT3-regulated gene products.
Supplementary Figure S3 from Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas
Authors: Garandeau David , Noujarède Justine , Leclerc Justine , Imbert Caroline , Garcia Virginie , Bats Marie-Lise , Rambow Florian , Gilhodes Julia , Filleron Thomas , Meyer Nicolas , Brayer Stéphanie , Arcucci Silvia , Tartare-Deckert Sophie , Ségui Bruno , Marine Jean-Christophe , Levade Thierry , Bertolotto Corine , Andrieu-Abadie Nathalie
Published: April 2023

Supplementary Figure S3 shows the effect of SKI-I on cell death in BRAFi-sensitive and -resistant melanoma cells
Supplementary Figure S4 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Authors: Andreev Julian , Thambi Nithya , Perez Bay Andres E. , Delfino Frank , Martin Joel , Kelly Marcus P. , Kirshner Jessica R. , Rafique Ashique , Kunz Arthur , Nittoli Thomas , MacDonald Douglas , Daly Christopher , Olson William , Thurston Gavin
Published: April 2023

HER2xPRLR bispecific antibodies with different HER2 and PRLR arms induced similar rates of HER2 degradation in T47D cells.
Supplementary Figure S1 from Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas
Authors: Garandeau David , Noujarède Justine , Leclerc Justine , Imbert Caroline , Garcia Virginie , Bats Marie-Lise , Rambow Florian , Gilhodes Julia , Filleron Thomas , Meyer Nicolas , Brayer Stéphanie , Arcucci Silvia , Tartare-Deckert Sophie , Ségui Bruno , Marine Jean-Christophe , Levade Thierry , Bertolotto Corine , Andrieu-Abadie Nathalie
Published: April 2023

Supplementary Figure S1 shows the effects of PLX on S1PR expression and cell death in BRAFi-sensitive and -resistant melanoma cells
Supplementary Table S1 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

Peptides used for LC-MRM based protein quantification for each kinase
Supplementary Fig.5 from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor
Authors: Wu Tingyu , Chen Wei , Zhong Yongwang , Hou Xiaodan , Fang Shengyun , Liu Chen-Ying , Wang Guanghui , Yu Tong , Huang Yu-Yang , Ouyang Xuesong , Li Henry Q.X. , Cui Long , Yang Yili
Published: April 2023

Bortezomib and KPT330 co-treatment inhibit patients-derived xenografts in nude mice.
Supplementary Figure S6 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

(A) TMA1 WEE1 and PAXIP1 staining (B) 95 cases and 10 controls were analyzed in TMA1, percentage breakdown by histology (C) Percentage breakdown by histology and WEE1/PAXIP1 staining status.
Supplementary Figure S5 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

Flow cytometry gating information for Figure 4E.
Supplementary Figure S4 from PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
Authors: Jhuraney Ankita , Woods Nicholas T. , Wright Gabriela , Rix Lily , Kinose Fumi , Kroeger Jodi L. , Remily-Wood Elizabeth , Cress W. Douglas , Koomen John M. , Brantley Stephen G. , Gray Jhanelle E. , Haura Eric B. , Rix Uwe , Monteiro Alvaro N.
Published: April 2023

(A) Experimental design timeline for apoptosis assays. (B) Caspase-3 activity assay in H522 cells (left panel) which express both WEE1 and PAXIP1 and in H1395 cells (right panel) which express PAXIP1 but no WEE1. (C-E) Caspase-3 activity was measured after treatment with AZD1775 at the time points indicated in H322 cells overexpressing full length PAXIP1 (C), or with PAXIP1 knockdown (D), or overexpressing TAP-PAXIP1 tBRCT C2 (E).
Supplementary table 4 from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Fold change levels from gene expression analyses of DEP domain containing 1 (DEPDC), Forkhead box M1 (FOXM1), and Lim domain only 4 (LM04). Control group is compared with treated group at 12 and 24 hours.
Supplementary table 3. from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Functional analyses of upregulated genes with a >4 fold changed. Specific functional categories were assigned by DAVID Bioinformatics Resources 6.7. Table 2 shows modified functions at 12 hours and table 3 at 24 hours.
Supplementary figure 4. from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

A) Effect on cell cycle of JQ1, vinorelbine, docetaxel, cisplatin and carboplatin. Cell cycle progression was examined in MDA-MB-231 and HS578T after 24 hours of treatment with JQ1 (0.2 ÂµM), vinorelbine (1nM), docetaxel (0.5 nM), cisplatin (2.5 ÂµM) and carboplatin (25 ÂµM), by flow cytometry using propidium iodide DNA staining, as described in "Material and methods". B) JQ1 induced-apoptosis and expression of PARP in MDA-MB-231 evaluated by flow cytometry at 48 hours after administration of JQ1 (0.2 ÂµM), docetaxel (0.5 nM) and cisplatin (2.5 ÂµM). Staining with annexin V and PARP antibody is described in "Material and methods".
Supplementary Figure legends from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
Authors: Pérez-Peña Javier , Serrano-Heras Gemma , Montero Juan Carlos , Corrales-Sánchez Verónica , Pandiella Atanasio , Ocaña Alberto
Published: April 2023

Figure legends
Figure S8 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Authors: Garcia Tamara B. , Snedeker Jonathan C. , Baturin Dmitry , Gardner Lori , Fosmire Susan P. , Zhou Chengjing , Jordan Craig T. , Venkataraman Sujatha , Vibhakar Rajeev , Porter Christopher C.
Published: April 2023

AZD1775 enhances the anti-proliferative effect of olaparib in AML patient samples with high baseline apoptosis or limited colony-forming ability. A and B. AML patient samples were treated with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 (200 nM) for 72 hr and analyzed for cell viability (A) and apoptosis induction (B). Live cell counts are normalized to cells receiving no treatment (NT). Results are shown as mean {plus minus} SEM of 2 technical replicates.
Figure S7 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Authors: Garcia Tamara B. , Snedeker Jonathan C. , Baturin Dmitry , Gardner Lori , Fosmire Susan P. , Zhou Chengjing , Jordan Craig T. , Venkataraman Sujatha , Vibhakar Rajeev , Porter Christopher C.
Published: April 2023

Combined AZD1775 and olaparib treatment is tolerated in vivo. A and B. Mice injected with a murine AML cell line were treated as described in the text. Complete blood counts (A) and weights (B) were obtained 10 days after leukemia transfer. Results are displayed as mean {plus minus} SEM from 2 independent experiments. *, P < 0.05. **, P < 0.01.
Supplementary Figures S1,S2;Supplementary Table 1; Supplementary Methods from Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma
Authors: Chen Baozhi , Trang Vinh , Lee Alex , Williams Noelle S. , Wilson Alexandra N. , Epstein Ervin H. , Tang Jean Y. , Kim James
Published: April 2023

Supplementary Figure S1. Structures of Triazole Antifungal Drugs; Supplementary Figure S2. Verification of Drug-resistance of SMO Mutants; Supplementary Table S1. Murine Serum Pharmacokinetic Parameters; Supplementary Methods
Figure S5 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Authors: Garcia Tamara B. , Snedeker Jonathan C. , Baturin Dmitry , Gardner Lori , Fosmire Susan P. , Zhou Chengjing , Jordan Craig T. , Venkataraman Sujatha , Vibhakar Rajeev , Porter Christopher C.
Published: April 2023

Cell cycle analysis of acute leukemia cells treated with olaparib and AZD1775. A. The indicated cell lines were treated with DMSO (vehicle), olaparib (2 uM), and/or AZD1775 (200 nM) for 48 hr then fixed and stained with propidium iodide. Results are shown as mean {plus minus} SEM from a minimum of two independent experiments. B. .MV4;11 cells were treated with DMSO (vehicle), olaparib (2 uM), and/or AZD1775 (200 nM) for 48 hr then fixed and stained with propidium iodide. Representative plots are displayed. C. Jurkat cells were treated with DMSO (vehicle), olaparib (2 uM), and/or AZD1775 (200 nM) for 48 hr then fixed and stained with propidium iodide. Representative plots are displayed.
Figure S4 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Authors: Garcia Tamara B. , Snedeker Jonathan C. , Baturin Dmitry , Gardner Lori , Fosmire Susan P. , Zhou Chengjing , Jordan Craig T. , Venkataraman Sujatha , Vibhakar Rajeev , Porter Christopher C.
Published: April 2023

FLT3-ITD does not enhance the combinatorial activity of AZD1775 and olaparib. The 32D cell line was transduced with FLT3-ITD or empty vector and treated with olaparib at the indicated doses and/or AZD1775 (100nM) in triplicate for 72 hours. Proliferation and viability were assessed by Cell Titer Glow, per the manufacturer's instructions, and normalized to the value of untreated (UT) cells. Data the mean {plus minus} SEM from 3 independent experiments.
Figure S2 from A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Authors: Garcia Tamara B. , Snedeker Jonathan C. , Baturin Dmitry , Gardner Lori , Fosmire Susan P. , Zhou Chengjing , Jordan Craig T. , Venkataraman Sujatha , Vibhakar Rajeev , Porter Christopher C.
Published: April 2023

AML and ALL cell lines display elevated homologous recombination in response to olaparib treatment. A-E. MV;411 (A), Molm13 (B), Jurkat (C), REH (D), and OCI-AML3 (E) cells received no treatment (NT) or were treated with olaparib (2 uM) for 72 hr then fixed and stained with anti-Rad51 (primary antibody), Alexo Fluor 488 conjugated secondary antibody, and DAPI. Representative images are shown. Rad51 foci per cell were quantified and are displayed to the right of the images. Results are shown and mean {plus minus} SEM calculated from a minimum of 50 cells per condition. ***, P < 0.001. ****, P < 0.0001.
Figure S3 from Glycoprotein-130 Expression Is Associated with Aggressive Bladder Cancer and Is a Potential Therapeutic Target
Authors: Martin Darryl T. , Shen Hongliang , Steinbach-Rankins Jill M. , Zhu Xi , Johnson Katelyn K. , Syed Jamil , Saltzman W. Mark , Weiss Robert M.
Published: April 2023

Fig S3. Cell migration of bladder cancer cells upon SC144 treatment.
Supplementary Materials from Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
Authors: Chen Jun , Kinoshita Taisei , Sukbuntherng Juthamas , Chang Betty Y. , Elias Laurence
Published: April 2023

Supplementary Tables 1 and 2; Supplementary Figure Legends
Supplemental Table 3 from Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
Authors: de Lint Klaas , Poell Jos B. , Soueidan Hayssam , Jastrzebski Katarzyna , Vidal Rodriguez Jordi , Lieftink Cor , Wessels Lodewyk F.A. , Beijersbergen Roderick L.
Published: April 2023

Normalized counts of shRNA constructs in GDC-0941-exposed and control populations
Supplementary Figure 4 from Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
Authors: Chen Jun , Kinoshita Taisei , Sukbuntherng Juthamas , Chang Betty Y. , Elias Laurence
Published: April 2023

Supplementary Figure S4. Ibrutinib inhibited the growth of BT-474 xenograft tumors and related signaling pathways in the tumor samples. (A) Inhibition of BT-474 xenograft growth in NOD-SCID mice by ibrutinib administered at once -daily doses of 3 mg/kg (â–²) or 16 mg/kg (â–¼) compared to vehicle control (â–€). Significance for differences from control is indicated by *(P<0.05) or **(P<0.01). (B) Comparison of pharmacokinetic parameters among different strains of mice dosed at 16 mg/kg and 48 mg/kg, PO. (C) Selected images for pERK staining from the BT-474 tumors dosed at 16 and 48 mg/kg, PO, and the data analysis. *P<0.05 and **P<0.01. Error bars represent standard deviation (SD). (D) Relative phosphorylation of AKT (pAKT/AKT) for harvested BT-474 tumors as for (C) at different timepoint. The density of each band was normalized to the first band of vehicle. The results for 48 mg/kg were graphed. Error bars represent SD.
Supplemental Table 1 from Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
Authors: de Lint Klaas , Poell Jos B. , Soueidan Hayssam , Jastrzebski Katarzyna , Vidal Rodriguez Jordi , Lieftink Cor , Wessels Lodewyk F.A. , Beijersbergen Roderick L.
Published: April 2023

Oligonucleotide sequences used in PCR reactions
Supplementary Table S1 and Figures S1 - S8 from mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL
Authors: Vo Thanh-Trang T. , Lee J. Scott , Nguyen Duc , Lui Brandon , Pandori William , Khaw Andrew , Mallya Sharmila , Lu Mengrou , Müschen Markus , Konopleva Marina , Fruman David A.
Published: April 2023

Supplemental Table S1: Stromal Dependent PDX samples; Supplemental Figure S1: Protection by mTOR inhibition is dose dependent; Supplemental Figure S2: Effect of mTOR inhibition on other chemotherapies; Supplemental Figure S3: Titration of PI3K/AKT/mTOR inhibitors; Supplemental Figure S4: Dose of dasatinib used inhibits ABL activity in Ph+ lines; Supplemental Figure S5: Killing effect of dasatinib alone can counteract the protection by mTOR inhibition; Supplemental Figure S6: Palbociclib alone is not cytotoxic; Supplemental Figure S7: Cell cycle inhibition reduces DNA damage by maintenance drugs; Supplemental Figure S8: mTOR inhibition decreases DHFR expression in some PDX lines
Supplemental Figure S1 from Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations
Authors: Gebreyohannes Yemarshet K. , Schöffski Patrick , Van Looy Thomas , Wellens Jasmien , Vreys Lise , Cornillie Jasmien , Vanleeuw Ulla , Aftab Dana T. , Debiec-Rychter Maria , Sciot Raf , Wozniak Agnieszka
Published: April 2023

Representative images of H&E, KIT and DOG1 staining performed in the xenograft models.
Supplementary Table 1 from Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line–Specific Effects from P-Glycoprotein–Induced Toxicity
Authors: Füredi András , Tóth Szilárd , Szebényi Kornélia , Pape Veronika F.S. , Türk Dóra , Kucsma Nóra , Cervenak László , Tóvári József , Szakács Gergely
Published: April 2023

Structure of the compounds analyzed in this study
Figure S4 from Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line–Specific Effects from P-Glycoprotein–Induced Toxicity
Authors: Füredi András , Tóth Szilárd , Szebényi Kornélia , Pape Veronika F.S. , Türk Dóra , Kucsma Nóra , Cervenak László , Tóvári József , Szakács Gergely
Published: April 2023

Supplementary Figure 4. Treatment stoppage does not lead to the re-expression of Pgp. MESSA-Dx5 cells were first treated with NSC57969to induce Pgp-loss, and then were cultured in normal medium. Lack of Pgp-activity at passage 17 and 28 is demonstrated with the calcein assay.
Figure S3 from Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line–Specific Effects from P-Glycoprotein–Induced Toxicity
Authors: Füredi András , Tóth Szilárd , Szebényi Kornélia , Pape Veronika F.S. , Türk Dóra , Kucsma Nóra , Cervenak László , Tóvári József , Szakács Gergely
Published: April 2023

Supplementary Figure 3. Brightfield image of the primary cell culture shown in Figure 6
Figure S1 from Combined PPARγ Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors
Authors: Leung Dilys T.H. , Nguyen Trang , Oliver Edwina May , Matti Juliana , Alexiadis Maria , Silke John , Jobling Thomas W. , Fuller Peter J. , Chu Simon
Published: April 2023

Figure S1. XIAP mRNA expression in GCT and GCT-derived cell line.
Supplementary Figure S5 from Chromatin Regulators as a Guide for Cancer Treatment Choice
Authors: Gurard-Levin Zachary A. , Wilson Laurence O.W. , Pancaldi Vera , Postel-Vinay Sophie , Sousa Fabricio G. , Reyes Cecile , Marangoni Elisabetta , Gentien David , Valencia Alfonso , Pommier Yves , Cottu Paul , Almouzni Geneviève
Published: April 2023

The SWI/SNF chromatin remodeler is associated with taxane response
Supplemental Table 5 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Authors: Thibault Stephane , Hu Wenyue , Hirakawa Brad , Kalabat Dalia , Franks Tania , Sung Tae , Khoh-Reiter Su , Lu Shuyan , Finkelstein Martin , Jessen Bart , Sacaan Aida
Published: April 2023

Table S5 shows normalized intensity of GSK3b, CDK4 and CDK6 in bone marrow and intestine of control rats.
Supplemental Table 2 from Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology
Authors: Thibault Stephane , Hu Wenyue , Hirakawa Brad , Kalabat Dalia , Franks Tania , Sung Tae , Khoh-Reiter Su , Lu Shuyan , Finkelstein Martin , Jessen Bart , Sacaan Aida
Published: April 2023

Table S2 shows IC50 values for CDK4/6 inhibitors in human and rat bone marrow.
Supplementary Figure S2 from Chromatin Regulators as a Guide for Cancer Treatment Choice
Authors: Gurard-Levin Zachary A. , Wilson Laurence O.W. , Pancaldi Vera , Postel-Vinay Sophie , Sousa Fabricio G. , Reyes Cecile , Marangoni Elisabetta , Gentien David , Valencia Alfonso , Pommier Yves , Cottu Paul , Almouzni Geneviève
Published: April 2023

A chromatin regulator gene panel distinguishes docetaxel high-responders and poor-responders
Supplementary Data - Figure Legends from Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Authors: Ilhan-Mutlu Aysegül , Osswald Matthias , Liao Yunxiang , Gömmel Miriam , Reck Martin , Miles David , Mariani Paola , Gianni Luca , Lutiger Beatrix , Nendel Viktor , Srock Stefanie , Perez-Moreno Pablo , Thorsen Frits , von Baumgarten Louisa , Preusser Matthias , Wick Wolfgang , Winkler Frank
Published: April 2023

Supplementary Data - Figure Legends
Supplementary Figures S1-S8 from Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen
Authors: Wang Xinning , Tsui Brian , Ramamurthy Gopolakrishnan , Zhang Ping , Meyers Joseph , Kenney Malcolm E. , Kiechle Jonathan , Ponsky Lee , Basilion James P.
Published: April 2023

Figure S1: Related PSMA ligands Figure S2: Schematic illustration for the synthesis of PSMA-1-SMCC and characterization of PSMA-1-SMCC Figure S3: Schematic illustration for the synthesis of PSMA-1-Pc413 and characterization of PSMA-1-Pc413 Figure S4: Schematic illustration for the synthesis of PSMA-1-IR700 and characterization of PSMA-1-IR700 Figure S5: Spectra of light sources Figure S6: Emission and absorbance spectra of PSMA-1-PDT agents Figure S7: Phototoxicity of PSMA-1-Pc413 was reduced in the presence of excess amount of Cys-CO-Glu. Figure S8: Maestro images of mice organs
Supplementary Table 2 from Induction of MNK Kinase–dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors
Authors: Pham Thao N.D. , Kumar Krishan , DeCant Brian T. , Shang Meng , Munshi Samad Z. , Matsangou Maria , Ebine Kazumi , Munshi Hidayatullah G.
Published: April 2023

Coefficient of drug interaction calculations
Supplementary Figures 1-7 from Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model
Authors: Lee Gina , Auffinger Brenda , Guo Donna , Hasan Tanwir , Deheeger Marc , Tobias Alex L. , Kim Jeong Yeon , Atashi Fatemeh , Zhang Lingjiao , Lesniak Maciej S. , James C. David , Ahmed Atique U.
Published: April 2023

Supplementary Figure 1. Expression of GSC markers increases with therapy in vitro and in vivo; Supplementary Figure 2. In vitro evaluation of stemness and TMZ sensitivity in the TMZ rechallenged model; Supplementary Figure 3. In vitro Evaluation of GSC-specific reporter system; Supplementary Figure 4. Differentiation of PDX GBM line after culturing in the media with 10% FBS; Supplementary Figure 5. GSC-specific promoters functionally represent the GSC subpopulation; Supplementary Figure 6. Differentiation of PDX GBM line after culturing in the media Bone Morphogenic Protein 2 (BMP2); Supplementary Figure 7. HIFs can modulate the expression of GSC markers
Supplementary Table 1 from Induction of MNK Kinase–dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors
Authors: Pham Thao N.D. , Kumar Krishan , DeCant Brian T. , Shang Meng , Munshi Samad Z. , Matsangou Maria , Ebine Kazumi , Munshi Hidayatullah G.
Published: April 2023

Effect of JQ1 on cytoskeletal genes
Summary of the IC50s of Delta-24-RGD in Tested Pancreatic Cancer Cell Lines from Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma
Authors: Dai Bingbing , Roife David , Kang Ya'an , Gumin Joy , Rios Perez Mayrim V. , Li Xinqun , Pratt Michael , Brekken Rolf A. , Fueyo-Margareto Juan , Lang Frederick F. , Fleming Jason B.
Published: April 2023

This table summarizes the dose (multiplicity of infection, MOI) of Delta-24-RGD that causes 50% of viability inhibition of infected pancreatic cancer cell lines (IC50).
Supplementary figure 1 from Long Noncoding RNA PVT1 Promotes Non–Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression
Authors: Wan Li , Sun Ming , Liu Guo-Jian , Wei Chen-Chen , Zhang Er-Bao , Kong Rong , Xu Tong-Peng , Huang Ming-De , Wang Zhao-Xia
Published: April 2023

The relationship between PVT1 and MYC. (A) The relationship between PVT1 expression and MYC mRNA levels was analyzed in lung cancer cells (data from TCGA). (B) and (C) The relationship between PVT1 expression and MYC mRNA levels was analyzed in the profile of NSCLC patient tissue from Gene Expression Omnibus (GEO).
Supplemental Figure Legends from Long Noncoding RNA PVT1 Promotes Non–Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression
Authors: Wan Li , Sun Ming , Liu Guo-Jian , Wei Chen-Chen , Zhang Er-Bao , Kong Rong , Xu Tong-Peng , Huang Ming-De , Wang Zhao-Xia
Published: April 2023

Figure Legend for Figure 1
Supplementary Figure 2 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

A schematic of the patient derived 3D-TGA method.
Supplementary Table S1 from A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers
Authors: Cho Sung-Yup , Han Jee Yun , Na Deukchae , Kang Wonyoung , Lee Ahra , Kim Jooyoung , Lee Jieun , Min Seoyeon , Kang Jinjoo , Chae Jeesoo , Kim Jong-Il , Park Hansoo , Lee Won-Suk , Lee Charles
Published: April 2023

Supplementary Table S1. List of previously reported MCL1-modulating agents.
Supplementary Figures from A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers
Authors: Cho Sung-Yup , Han Jee Yun , Na Deukchae , Kang Wonyoung , Lee Ahra , Kim Jooyoung , Lee Jieun , Min Seoyeon , Kang Jinjoo , Chae Jeesoo , Kim Jong-Il , Park Hansoo , Lee Won-Suk , Lee Charles
Published: April 2023

Supplementary Figure S1. Expression of BCL2L1 and BCL2 in CRC cell lines; Supplementary Figure S2. Estimated BCL2L1 copy numbers of CRC patients by droplet digital PCR (ddPCR); Supplementary Figure S3. Screening of MCL1-modulating agents for synergistic effect with ABT- 263 in KRAS-mutated and BCL2L1-amplified CRC cells (SW620); Supplementary Figure S4. Screening of MCL1-modulating agents for synergistic effect with ABT- 263 in KRAS wild and BCL2L1-diploid CRC cells (SNU1684); Supplementary Figure S5. Effect of ABT-263 and YM-155 combination treatment in CRC cell lines with different KRAS/BRAF mutation status and BCL2L1 copy numbers; Supplementary Figure S6. Effect of ABT-263 and YM-155 in siBCL2L1-treated SW620 cells; Supplementary Figure S7. The quantification of MCL1 protein expression and levels of cleaved caspase 3 and cleaved PARP from Figure 2; Supplementary Figure S8. The quantification of MCL1 protein expression and levels of cleaved caspase 3 and cleaved PARP from Supplementary Figure S5; Supplementary Figure S9. Estimation of apoptosis induced by combination of ABT-263 and YM- 155; Supplementary Figure S10. The quantification of protein expression levels from Figure 3; Supplementary Figure S11. The quantification of protein expression levels from Figure 4; Supplementary Figure S12. The quantification of protein expression levels from Figure 5; Supplementary Figure S13. In vivo efficacy of ABT-263 and YM-155 treatment in CRC cell line xenograft models.
Supplementary Table 1, Table 2, Table 3 from MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival
Authors: Radoul Marina , Chaumeil Myriam M. , Eriksson Pia , Wang Alan S. , Phillips Joanna J. , Ronen Sabrina M.
Published: April 2023

Table S1. GS-2 orthotopic tumor model: in vivo single voxel 1H MRS; Table S2. GS-2 orthotopic tumor model: ex vivo 1H HR-MAS MR Spectroscopy; Table S3. U87-MG orthotopic tumor model: ex vivo 1H HR-MAS MR Spectroscopy.
Supplementary Figures 1-9 from Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma
Authors: Aboukameel Amro , Muqbil Irfana , Senapedis William , Baloglu Erkan , Landesman Yosef , Shacham Sharon , Kauffman Michael , Philip Philip A. , Mohammad Ramzi M. , Azmi Asfar S.
Published: April 2023

Supplementary Figure1. IC50 analysis for PAM activity across a panel of cell lines. MTT assay was performed at 72 hrs; Supplementary Figure 2. PDAC cell lines were grown at a density of 50,000 cells per well overnight and exposed to PAMs (at 5000 nM for 96 hrs). Apoptosis analysis was performed using Annexin V FITC assay; Supplementary Figure 3. Impact of PAK4 siRNA silencing on the activity of PAMs; Supplementary Figure 4. PAMs induce cancer cell selective cell cycle arrest; Supplementary Figure 5. PAMs suppress PDAC cellular migration; Supplementary Figure 6. DU145 prostate cancer cell line were grown in 100 mm petri dish overnight; Supplementary Figure 7: Flow sorted MiaPaCa-2 CSCs (CD44CD133EpCAM+++) as described in methods section were grown in six well plates at a density of 50,000 cells per well and exposed to 5 μM concentration of PAMs for 72 hrs; Supplementary Figure 8. PAMs molecularly synergize with gemcitabine and oxaliplatin; Supplementary Figure 9. Single agent and combination anti-tumor activity of PAM in sub-cutaneous PDAC tumor models.